US 7,501,450 B2
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
Limor Tessler, Natanya (Israel); Judith Aronhime, Rehovot (Israel); Revital Lifshitz-Liron, Herzlia (Israel); Dalia Maidan-Hanoch, Kfar Yona (Israel); and Nir Hasson, Meitar (Israel)
Assigned to Teva Pharaceutical Industries Ltd., Petah Tiqva (Israel)
Filed on Feb. 19, 2003, as Appl. No. 10/370,897.
Application 10/370897 is a continuation in part of application No. 09/997126, filed on Nov. 29, 2001.
Claims priority of provisional application 60/425325, filed on Nov. 12, 2002.
Claims priority of provisional application 60/357181, filed on Feb. 15, 2002.
Claims priority of provisional application 60/326529, filed on Oct. 01, 2001.
Claims priority of provisional application 60/312144, filed on Aug. 13, 2001.
Claims priority of provisional application 60/281872, filed on Apr. 05, 2001.
Claims priority of provisional application 60/267897, filed on Feb. 09, 2001.
Claims priority of provisional application 60/250072, filed on Nov. 30, 2000.
Prior Publication US 2003/0212279 A1, Nov. 13, 2003
Int. Cl. A61K 31/40 (2006.01); C07D 207/325 (2006.01)
U.S. Cl. 514—423  [548/537] 3 Claims
 
1. Solid crystalline atorvastatin hemi-calcium Form IX characterized by a powder X-ray diffraction pattern generated using CuKα radiation substantially as follows
substantially as depicted in FIG. 6.